Roche’s Tecen­triq scoops up a big win in small cell lung can­cer, grab­bing the lead in front­line cas­es

Roche’s Genen­tech has scored a land­mark suc­cess in treat­ing small cell lung can­cer, re­port­ing that its PD-L1 check­point Tecen­triq plus chemo helped pa­tients live longer when they re­ceived the com­bo as a front­line ther­a­py. And the score on IM­pow­er133  should put it in the lead in that sec­tor — for now. 

Falling on the heels of some set­backs, Genen­tech ex­ecs are re­port­ing that their com­bi­na­tion ap­proach of­fered sta­tis­ti­cal­ly sig­nif­i­cant re­sults for both over­all sur­vival as well as pro­gres­sion-free sur­vival. The beat over the con­trol arm was al­so iden­ti­fied at an in­ter­im stage, al­low­ing Roche to ac­cel­er­ate plans to get this in­to the hands of reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.